Lexaria Bioscience (LEXX) & Its Competitors Head to Head Analysis

Lexaria Bioscience (NASDAQ:LEXX) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Lexaria Bioscience to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Lexaria Bioscience and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexaria Bioscience	$710,000.00	-$11.90 million	-0.88
Lexaria Bioscience Competitors	$3.54 billion	$3.17 billion	554.50

Lexaria Bioscience’s rivals have higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Lexaria Bioscience has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Lexaria Bioscience’s rivals have a beta of -4.04, meaning that their average share price is 504% less volatile than the S&P 500.

Profitability

This table compares Lexaria Bioscience and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Lexaria Bioscience Competitors	-2,372.59%	-220.82%	-15.99%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1	0	1	0	2.00
Lexaria Bioscience Competitors	7792	13886	25777	1037	2.41

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 400.00%. As a group, “Pharmaceuticals” companies have a potential upside of 25.58%. Given Lexaria Bioscience’s higher possible upside, equities analysts clearly believe Lexaria Bioscience is more favorable than its rivals.

Insider & Institutional Ownership

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lexaria Bioscience rivals beat Lexaria Bioscience on 9 of the 13 factors compared.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.